Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:The_Upjohn_Company
|
| gptkbp:activities |
dopamine receptor antagonist
serotonin receptor antagonist |
| gptkbp:appointed_by |
sublingual tablet
|
| gptkbp:approves |
gptkb:2009
gptkb:FDA |
| gptkbp:brand |
Saphris
|
| gptkbp:clinical_trial |
Phase III
psychotic disorders maintenance treatment of bipolar disorder acute mania mixed episodes |
| gptkbp:contraindication |
severe hepatic impairment
hypersensitivity to asenapine |
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:dosage_form |
5-10 mg twice daily
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
sublingual film
|
| https://www.w3.org/2000/01/rdf-schema#label |
Asenapine
|
| gptkbp:ingredients |
C17 H16 N2
|
| gptkbp:interacts_with |
CY P2 D6 inhibitors
CY P1 A2 inhibitors |
| gptkbp:invention |
gptkb:2023
|
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_used_for |
schizophrenia
bipolar disorder |
| gptkbp:lifespan |
24 hours
|
| gptkbp:manager |
sublingual
|
| gptkbp:marketed_as |
Saphris
|
| gptkbp:metabolism |
liver
|
| gptkbp:premiered_on |
1-2 hours
|
| gptkbp:research_areas |
patient compliance
pharmacogenomics drug interactions long-term effects bipolar disorder treatment neuropharmacology schizophrenia treatment dosing strategies side effect management antipsychotic drug development |
| gptkbp:side_effect |
seizures
drowsiness dry mouth weight gain increased appetite hyperglycemia extrapyramidal symptoms QT prolongation neuroleptic malignant syndrome agranulocytosis |
| gptkbp:type_of |
344-20-1
|